<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37178706</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.</ArticleTitle><Pagination><StartPage>1062</StartPage><EndPage>1071</EndPage><MedlinePgn>1062-1071</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(23)00139-1</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(23)00139-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine-derived poliovirus type 2 outbreaks. Bivalent oral poliovirus vaccine (bOPV; containing Sabin types 1 and 3) is the vaccine of choice for type 1 and type 3 outbreak responses. We aimed to assess immunological interference between nOPV2 and bOPV when administered concomitantly.</AbstractText><AbstractText Label="METHODS">We conducted an open-label, non-inferiority, randomised, controlled trial at two clinical trial sites in Dhaka, Bangladesh. Healthy infants aged 6 weeks were randomly assigned (1:1:1) using block randomisation, stratified by site, to receive nOPV2 only, nOPV2 plus bOPV, or bOPV only, at the ages of 6 weeks, 10 weeks, and 14 weeks. Eligibility criteria included singleton and full term (≥37 weeks' gestation) birth and parents intending to remain in the study area for the duration of study follow-up activities. Poliovirus neutralising antibody titres were measured at the ages of 6 weeks, 10 weeks, 14 weeks, and 18 weeks. The primary outcome was cumulative immune response for all three poliovirus types at the age of 14 weeks (after two doses) and was assessed in the modified intention-to-treat population, which was restricted to participants with adequate blood specimens from all study visits. Safety was assessed in all participants who received at least one dose of study product. A non-inferiority margin of 10% was used to compare single and concomitant administration. This trial is registered with ClinicalTrials.gov, NCT04579510.</AbstractText><AbstractText Label="FINDINGS">Between Feb 8 and Sept 26, 2021, 736 participants (244 in the nOPV2 only group, 246 in the nOPV2 plus bOPV group, and 246 in the bOPV only group) were enrolled and included in the modified intention-to-treat analysis. After two doses, 209 (86%; 95% CI 81-90) participants in the nOPV2 only group and 159 (65%; 58-70) participants in the nOPV2 plus bOPV group had a type 2 poliovirus immune response; 227 (92%; 88-95) participants in the nOPV2 plus bOPV group and 229 (93%; 89-96) participants in the bOPV only group had a type 1 response; and 216 (88%; 83-91) participants in the nOPV2 plus bOPV group and 212 (86%; 81-90) participants in the bOPV only group had a type 3 response. Co-administration was non-inferior to single administration for types 1 and 3, but not for type 2. There were 15 serious adverse events (including three deaths, one in each group, all attributable to sudden infant death syndrome); none were attributed to vaccination.</AbstractText><AbstractText Label="INTERPRETATION">Co-administration of nOPV2 and bOPV interfered with immunogenicity for poliovirus type 2, but not for types 1 and 3. The blunted nOPV2 immunogenicity we observed would be a major drawback of using co-administration as a vaccination strategy.</AbstractText><AbstractText Label="FUNDING">The US Centers for Disease Control and Prevention.</AbstractText><CopyrightInformation>Copyright © 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Amanda L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: lxq6@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaman</LastName><ForeName>Khalequ</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoque</LastName><ForeName>Masuma</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estivariz</LastName><ForeName>Concepcion F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konopka-Anstadt</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainou</LastName><ForeName>Bernardo A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Stephanie D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lickness</LastName><ForeName>Jacquelyn S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yunus</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snider</LastName><ForeName>Cynthia J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yiting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coffee</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abid</LastName><ForeName>Talha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallansch</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberste</LastName><ForeName>M Steven</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vertefeuille</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Abhijeet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04579510</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Infect Dis. 2023 Sep;23(9):992-994. doi: 10.1016/S1473-3099(23)00133-0</RefSource><PMID Version="1">37178705</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001459" MajorTopicYN="N" Type="Geographic">Bangladesh</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>14</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37178706</ArticleId><ArticleId IdType="mid">NIHMS1903196</ArticleId><ArticleId IdType="pmc">PMC10503264</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00139-1</ArticleId><ArticleId IdType="pii">S1473-3099(23)00139-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dowdle WR, Cochi SL. Global eradication of poliovirus: history and rationale. In: Semler BL, Wimmer E, eds. Molecular biology of picornaviruses. Washington, DC: ASM Press, 2002: 473–80.</Citation></Reference><Reference><Citation>Rachlin A, Patel JC, Burns CC, et al. Progress toward polio eradication—worldwide, January 2020–April 2022. MMWR Morb Mortal Wkly Rep 2022; 71: 650–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098249</ArticleId><ArticleId IdType="pubmed">35552352</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R, Kew O, Cochi S, Aylward RB. Poliovirus vaccine—live. In: Plotkin S, Orenstein WA, Offit PA, eds. Vaccines, 6th edn. Philadelphia, PA: Elsevier Saunders, 2012.</Citation></Reference><Reference><Citation>Patriarca P, Linkins R, Sutter R, Orenstein W. Optimal schedule for the administration of oral poliovirus vaccine. In Kurstak E, ed. Measles and poliomyelitis, Austria: Springer-Verlag, 1993: 303–13.</Citation></Reference><Reference><Citation>Ogra PL, Fishaut M, Gallagher MR. Viral vaccination via the mucosal routes. Rev Infect Dis 1980; 2: 352–69.</Citation><ArticleIdList><ArticleId IdType="pubmed">6997965</ArticleId></ArticleIdList></Reference><Reference><Citation>Estívariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013; 3: 309–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10395005</ArticleId><ArticleId IdType="pubmed">23759252</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyesh-Melnick M, Melnick JL, Rawls WE, et al. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol 1967; 86: 112–36.</Citation><ArticleIdList><ArticleId IdType="pubmed">4378110</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, Jorba J, Henderson E, et al. Update on vaccinederived poliovirus outbreaks—worldwide, January 2020–June 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1691–99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8659190</ArticleId><ArticleId IdType="pubmed">34882653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine—worldwide, 2016. MMWR Morb Mortal Wkly Rep 2016; 65: 934–38.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, O’Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science 2020; 368: 401–05.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, Bujaki E, Dolan PT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe 2020; 27: 736–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt JL, Campagnoli R, Vincent A, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines 2020; 5: 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Sáez-Llorens X, Bandyopadhyay AS, Gast C, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet 2021; 397: 27–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a doubleblind, single-centre phase 1 study. Lancet 2019; 394: 148–58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R, Mercer L, Gast C, et al. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. NPJ Vaccines 2022; 7: 19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8837630</ArticleId><ArticleId IdType="pubmed">35149714</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I, Leroux-Roels I, Bandyopadhyay AS, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet 2021; 397: 39–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay A
Why is polio making a “comeback” and what can we do about it?
2023. https://speakingofmedicine.plos.org/2023/03/17/why-is-polio-making-a-comeback-and-what-can-we-do-about-it/
(accessed April 21,
2023).</Citation></Reference><Reference><Citation>Martin J, Burns CC, Jorba J, et al. Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing—worldwide, March–October 2021. MMWR Morb Mortal Wkly Rep 2022; 71: 786–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">35709073</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: World Health Organization, 2006.</Citation></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol 2016; 1387: 145–76.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerloff N, Sun H, Mandelbaum M, et al. Diagnostic assay development for poliovirus eradication. J Clin Microbiol 2018; 56: e01624–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5786708</ArticleId><ArticleId IdType="pubmed">29212703</ArticleId></ArticleIdList></Reference><Reference><Citation>Gast C, Bandyopadhyay AS, Sáez-Llorens X, et al. Fecal shedding of 2 novel live attenuated oral poliovirus type 2 vaccine candidates by healthy infants administered bivalent oral poliovirus vaccine/inactivated poliovirus vaccine: 2 randomized clinical trials. J Infect Dis 2022; 226: 852–61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9470102</ArticleId><ArticleId IdType="pubmed">34610135</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Abbo A, Culley BS, Reed GW, et al. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Pediatr Infect Dis J 1995; 14: 100–06.</Citation><ArticleIdList><ArticleId IdType="pubmed">7746690</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Zaman K, Estívariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine 2015; 33: 6816–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10423714</ArticleId><ArticleId IdType="pubmed">26476367</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010; 376: 1682–88.</Citation><ArticleIdList><ArticleId IdType="pubmed">20980048</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K, Estívariz CF, Morales M, et al. Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial. Lancet Infect Dis 2018; 18: 657–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10495755</ArticleId><ArticleId IdType="pubmed">29571817</ArticleId></ArticleIdList></Reference><Reference><Citation>Estívariz CF, Anand A, Gary HE Jr, et al. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis 2015; 15: 898–904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10406135</ArticleId><ArticleId IdType="pubmed">26093980</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Laender F, Palmeira G, et al. Randomised trial of alternative formulations of oral poliovaccine in Brazil. Lancet 1988; 1: 429–33.</Citation><ArticleIdList><ArticleId IdType="pubmed">2893864</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K, Bandyopadhyay AS, Hoque M, et al. Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial. Lancet 2023; 14: 131–39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9860215</ArticleId><ArticleId IdType="pubmed">36495882</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardemil CV, Estivariz C, Shrestha L, et al. The effect of diarrheal disease on bivalent oral polio vaccine (bOPV) immune response in infants in Nepal. Vaccine 2016; 34: 2519–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10552718</ArticleId><ArticleId IdType="pubmed">27085172</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>